If an insurance plan doesnt cover Wegovy or Zepbound, these out-of-pocket programs with Novo Nordisk and Eli Lilly can be a way for patients to still access these drugs. In the last few years, both drugs had been in short supply due to manufacturing issues and high demand
Filippello A, Di Mauro S, Scamporrino A, Malaguarnera R, Torrisi SA, Leggio GM, et al
Note that CVS Caremark removed Zepbound from its standard formularies in mid-2025, so a patient with Aetna can have Mounjaro covered for diabetes while Zepbound is simultaneously off-formulary
Why GLP-1 Receptor Agonists Are Becoming Essential Cardiovascular Drugs Introduction Individuals with type 2 diabetes face markedly elevated risks for myocardial infarction, ischemic stroke, heart failure, and cardiovascular death
To our knowledge, this study represents the largest cohort to date investigating the association between GLP-1 RAs and cardiovascular and kidney outcomes in KTRs with T2DM